Moreover, molecular details on how wild-type or mutant protein tau inflicts the clinical phenotype in a specific tauopathy, will provide an interesting outlook on novel therapeutic targets for neurodegenerative diseases, caused or mediated in first or second order by protein tau. The gene discussed is MAPT; the disease is neurodegenerative disease.